Myc
Myc refers to a gene encoding the MYC family of transcription factors, which are central regulators of cell growth, metabolism, proliferation, differentiation, and apoptosis.
Myc refers to a gene encoding the MYC family of transcription factors, which are central regulators of cell growth, metabolism, proliferation, differentiation, and apoptosis. In biomedical research, MYC is widely recognized as a potent transcriptional hub whose activity must be tightly controlled, because abnormal MYC signaling is associated with diverse pathological processes, including cancer, metabolic dysfunction, and tissue degeneration.
At the molecular level, MYC functions by regulating the expression of numerous downstream target genes involved in biosynthesis, energy metabolism, and cell-cycle progression. Its abundance and activity are controlled not only at the transcriptional level but also through post-translational mechanisms such as ubiquitination and proteasomal degradation. Recent studies have also placed MYC-family signaling in broader disease contexts, including diabetic retinopathy, disc degeneration, and jasmonate-mediated plant stress responses, where MYC-related pathways influence inflammatory, metabolic, or developmental outputs.
Rebuilt from PubMed 5 Sept 2026 · no new papers today
Where the papers sit
9 papers study myc directly. Those 9 do not group into themes. MYC recurs as a molecular associate across unrelated cancers, environmental toxicology and disc degeneration, alongside computational screens and experimental studies. The set shares no disease or mechanism, so it shows no common therapeutic direction. They are no more alike than papers drawn from anywhere in the corpus. 1 paradigm shift follows.
MYC can be controlled through protein degradation rather than treated only as an undruggable transcriptional driver
The stapled-peptide MAX-7 study in triple-negative breast cancer, the ISOC1-modRNA hydrogel study in rat intervertebral disc degeneration, and the DNMT1–FBXO32 study in diabetic-retinopathy-associated endothelial cells show independently that MYC protein turnover is a disease-controlling mechanism rather than merely a downstream readout or transcriptional target. MAX-7 depletes MYC through chaperone-mediated autophagy while bypassing the ubiquitin–proteasome system; ISOC1 promotes BIRC6-mediated ubiquitination and proteasomal MYC degradation; and FBXO32, an E3 ligase, regulates MYC stability during endothelial injury and glycolytic reprogramming 42444318Jul 42366417Jun 42348038Jun. This replaces the set’s prevailing emphasis on inhibiting MYC-associated transcriptional programs with a broader strategy in which MYC abundance itself can be therapeutically or biologically redirected through distinct degradation pathways.
Recent Findings on Myc
These studies repeatedly nominate MYC as a molecular node in breast cancer and immune-toxicology models. Network toxicology, GeneCards, machine learning, and molecular docking placed MYC with EGFR among core targets linked to methyl 4-hydroxybenzoate-associated breast cancer and microplastics-induced miscarriage 42665765Aug42629697Aug. The breast cancer studies further associated MYC with macrophage-related tumor microenvironment changes and mitophagy-related pathways, while berberine targeted MYC among several genes in molecular docking and in vitro experiments 42665765Aug42645668Aug. MAX-7 provided the strongest experimental direction by driving lysosome-dependent MYC depletion through chaperone-mediated autophagy and suppressing triple-negative breast cancer in cells and xenografts 42444318Jul. The field is moving from computational target prediction toward experimental MYC degradation and mechanism-guided therapeutic development.
These papers place MYC in disease progression, but they do not establish a common SMARCA2-specific mechanism. A Burkitt lymphoma case linked MYC rearrangement to paraneoplastic myopathy, elevated serum CPK levels, axillary lymphadenopathy, and rapid improvement after chemotherapy 42680716Sep. The esophageal adenocarcinoma study evaluated MYC amplification among molecular co-alterations in SMARCA2/4-deficient tumors, while emphasizing MET amplification, stromal-immune features, and risk stratification 42527418Jul. In a separate regenerative model, ISOC1 promoted BIRC6-mediated MYC degradation, suppressed SBSN, and reduced apoptosis and mitochondrial dysfunction in nucleus pulposus cells 42366417Jun. These differing findings support context-specific biomarker development and targeted control of MYC stability rather than a single SMARCA2-linked pathway.
These studies show that MYC activity or stability can reshape cellular stress metabolism, but they identify different downstream effects. In colorectal cancer, MYC directly increased FTH1 and GPX4 transcription, suppressed ferroptosis, and conferred oxaliplatin resistance; MYC knockdown increased intracellular Fe2⁺ and reactive oxygen species 42560559Aug. Sorafenib enhanced oxaliplatin sensitivity in resistant colorectal cancer cells, supporting the MYC-FTH1/GPX4-ferroptosis axis as a therapeutic target 42560559Aug. In diabetic retinopathy-associated endothelial cells, DNMT1 methylated the FBXO32 promoter, reduced FBXO32-mediated Myc ubiquitination and degradation, and promoted glycolytic reprogramming, inflammation, and cell migration 42348038Jun. The therapeutic direction therefore separates ferroptosis-based treatment sensitization from DNMT1-FBXO32-Myc control of endothelial dysfunction.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-07-02. Last written: 2026-09-03 by GPT. Drafted by language models from published abstracts; not medical advice.